Effects of non-steroidal antiallergic eyedrops on the complement-mediated histamine release from human cells

Ocular Immunology and Inflammation

Volumn 5, Issue 1, 1997, Pages 11-18

  Goldschmidt, P ^a   Couturier, C ^b   Haeffner Cavaillon, N ^b   Kazatchkine, M ^b   Herman, D ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL BROUSSAIS   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Basophil degranulation; Complement; Disodium cromoglycate; ELISA; Histamine; Levocabastine; Lodoxamide; N acetyl aspartyl glutamic acid sodium salt; Non steroidal antiallergics

Indexed keywords

COMPLEMENT; EYE DROPS; HISTAMINE;

ALLERGIC REACTION; ARTICLE; BASOPHIL; CLINICAL ARTICLE; COMPLEMENT SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; HOUSE DUST ALLERGY; HUMAN; HUMAN CELL; LEUKOCYTE; MAST CELL; POLLEN ALLERGY;

EID: 0030984792     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.3109/09273949709085045     Document Type: Article

References (32)

1. Cooper JA. Vegetable dust and airway disease, Inflammatory mechanism. Environm Hlth Persp 1986; 66:7-15.
2. Proud D, Sweet J, Stein P, Settipane RA, Kagey-Sobotka A, Friedlaender MH, Lichtenstein LM. Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen. J Allergy Clin Immunol 1990; 85:896-905.
3. Abelson MB, Bair RS, Allansmith MR. Tear histamine levels in vernal conjunctivitis and other ocular inflammations. Ophthalmology 1980; 87:812.
4. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. Am Rev Resp Dis 1983; 128:597.
5. Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 65:313.
6. Salzano FA, d'Angelo L, Motta S, delPrete A, Gentile M, Motta G. Allergic rhinoconjunctivitis: diagnostic and clinical assessment. Rhinology 1992; 30:265-275.
7. Fraser DG, Regal JF. Recombinant human C5a-induced broncho-constriction in the guinea pig: inhibition by an Hi antagonist after depletion of circulating granulocytes and platelets. J Pharmacol Exp Therapeut 1991; 259:1213-1219.
8. Halprin G, Buckley CE, Zitt MJ, McMahon SM. Changes in arteriovenous complement activity induced by inhalation challenge. Am Rev Resp Dis 1973; 108:343-352.
9. Carroll MP, Durham SR, Walsh G. Kay AB. Activation of neutrophils and monocytes after allergen- and histamine-induced broncho-constriction. J Allergy Clin Immunol 1985: 75:290-296.
10. Larsen GL, Shampain MP, Marsh WR, Behrens BL. An animal model of the late asthmatic response to antigen challenge. In: Asthma: Physiology. Immunopharmacology and Treatment. Kay AB, Austen KF, Lichtenstein LM (editors). Academic Press Ine, London 1984, pp 245-262.
11. Panzani RC, Mercier P, Delord Y, Riva G, Falagiani P, Reviron D, Auquier P. Prevalence of patent and latent atopy among a general normal adult population in the south east of France by RAST investigation and correlation with circulating total IgE levels. Allergol Immunopathol 1993; 21:211-219.
12. Stephan V, Khur J, Urbanek R. Anti-IgE- and complement-induced histamine release from peripheral leukocytes in normals and atopics. Int Arch Allergy Immunol 1989; 90:326-330.
13. Gurgenidze GV, Baraban EI, Gamkrelidze AG. Local humoral immunity in patients with pollen allergy. Allergol Immunopathol 1990; 18:315-319.
14. Ciprandi G, Cerqueti PM, Sacca S, Ciurlo G, Tosca MA, Canonica GW. Non-steroidal treatment of pollen-induced conjunctivitis: comparison of different pharmacological protocols. Allergy 1991; 46:393-395.
15. Dechant KL, Goa KL. Levocabastine: A review of its pharmalogical properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991; 41:202-224.
16. Ahelson MB, Georges MA, Schaefer K, Smith LM. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis. J Allergy Clin Immunol 1994; 94:458-464.
17. Knight A. The role of levocabastine in the treatment of allergic rhinoconjunctivitis. Br J Clin Practice 1994; 48:139-143.
18. Leino M, Montan P, Nja F. A double-blind group comparative study of ophthalmic sodium cromoglycate, 2% four times daily and 4% twice daily, in the treatment of seasonal allergic conjunctivitis. Allergy 1994; 49:147-151.
19. Caldwell DR, Verin P, Hartwich-Young R, Meyer SM, Drake MM. Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal keratoconjunctivitis. Am J Ophthalmol 1992; 113:632-637.
20. Santos CI, Huang AJ, Abelson MB, Foster CS, Friedlaender M, McCulley JP. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am J Ophthalmol 1994; 117:488-497.
21. Magyar P, Gyori Z, Mark Z, Hutas I. The protective effect of N-acetyl-aspartyl-glutamate (NAAGA) against nasal obstruction provoked by antigen in allergic rhinitis. Allergy 1993; 48:631-633.
22. Althaus MA, Pichler WJ. Nasal application of a gel formulation of N-acetyl-aspartyl glutamic acid (NAAGA) compared with placebo and disodium cromoglycate in the symptomatic treatment of pollinosis. Allergy 1994;49:184-188.
23. Miadonna A, Cottini M, Candiani C, Tedeschi A. Modulation of allergen-induced nasal symptoms and mediator release by treatment with N-acetyl-aspartyl-glutamate (ZY 15106). Eur J Clin Pharmacol 1994; 46:127-131.
24. EAACI Sub-Committee for Skin Test. Skin test used in type I allergy testing. Position Paper. Allergy 44 (suppl.); 1990; 22-30.
25. Lichtenstein LM, Osier AG. Studies on the mechanism of hypersensitivity phenomena. IX: Histamine release from human basophil leukocytes by ragweed pollen antigens. J Exp Med 1964; 120:507-530.
26. Lau HYA, Pearce FL. Dual effect of antihistamines on rat peritoneal mast cells: induction and inhibition of histamine release. Agents and Actions 1985; 16:176-178.
27. Mota I, Dias Da Silva W. The anti-anaphylactic and histamine-releasing properties of the antihistamines. The effect on the mast cells. Br J Pharmacol 1960; 15:396-404.
28. Church MK, Gradidge CF. Inhibition of histamine release from human lung in vitro by anti-histamines and related drugs. Br J Pharmacol 1980; 69:663-667.
29. de Weck AL, Derer T, Bischoff SC, Takafuji S. The effects of terfenadine on the immediate and late-phase reactions mediated by immunoglobulin. E Int Arch Allergy Immunol 1993; 101:326-332.
30. Okayama Y, Benyon RC, Lowman MA, Church MK. In vitro effects of H1-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin. Allergy 1994; 49:246-253.
31. Tasaka K, Kamei C, Akagi M, Mio M, Shirasaka T, Chokki M. Antiallergic profile of the novel H1-antihistaminic compound levocabastine. Arzneimitt Forsch (Drug Res), 1993; 43:1331-1337.
32. Thomas SG, Beveridge AA. The novel marine natural product plocamadiene A causes histamine release from mast cells of the guineapig and rat in vitro. Clin Exp Pharmacol Physiol 1993; 20:223-229.